Cargando…

Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment

Prostate cancer (CaP) is one of the leading causes of death in men worldwide. Much attention has been given on its prevention and treatment strategies, including targeting the regulation of 5-alpha-Reductase (5αR) enzyme activity, aimed to limit the progression of CaP by inhibiting the conversion of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azizi, Aziemah, Mumin, Nuramalina H, Shafqat, Naeem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276191/ https://www.ncbi.nlm.nih.gov/pubmed/34316358 http://dx.doi.org/10.12688/f1000research.51066.3

Ejemplares similares

In Silico Analysis of PORD Mutations on the 3D Structure of P450 Oxidoreductase
por: Nurhafizuddin, Muhammad, et al.
Publicado: (2022)

5-alpha-reductase and the development of the human prostate
por: Radmayr, C., et al.
Publicado: (2008)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

Role of 5 alpha-reductase inhibitors in the management of prostate cancer
por: Hudak, Steven J, et al.
Publicado: (2006)

Prostate Cancer Mortality and Use of 5-Alpha Reductase Inhibitors
por: Foldes, Cara A., et al.
Publicado: (2020)

5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity
por: Wang, Ziting, et al.
Publicado: (2023)

5-alpha reductase inhibitors use in prostatic disease and beyond
por: Chislett, Bodie, et al.
Publicado: (2023)

Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications
por: Wang, Kai, et al.
Publicado: (2014)

Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis
por: Deng, Tuo, et al.
Publicado: (2020)

Association of 5-alpha-reductase inhibitor and prostate cancer incidence and mortality: a meta-analysis
por: Hu, Xu, et al.
Publicado: (2020)

Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors
por: Falagario, Ugo G., et al.
Publicado: (2023)

Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia
por: Cho, Kang Jun, et al.
Publicado: (2011)

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
por: Kim, Won, et al.
Publicado: (2014)

Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer
por: Seok, Jaekwon, et al.
Publicado: (2023)

Is Transforming Growth Factor-β Signaling Activated in Human Hypertrophied Prostate Treated by 5-Alpha Reductase Inhibitor?
por: Kim, Hye Kyung, et al.
Publicado: (2013)

Anti-Cancer Activity of Phytochemicals Targeting Hypoxia-Inducible Factor-1 Alpha
por: Yun, Ba Da, et al.
Publicado: (2021)

Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2017)

The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
por: Ayodele, Olulade, et al.
Publicado: (2021)

Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer
por: Delgado-Balderas, Jesus Rolando, et al.
Publicado: (2020)

The effect of 5 alpha-reductase inhibitor therapy on prostate cancer detection in the era of multi-parametric magnetic resonance imaging
por: Kim, Jung Kwon, et al.
Publicado: (2019)

The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population
por: Choi, Se Young, et al.
Publicado: (2015)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
por: Kim, Jae Heon, et al.
Publicado: (2018)

Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment
por: Busato, Wilson F. S.
Publicado: (2020)

Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia
por: Choi, Gwang Seong, et al.
Publicado: (2016)

A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland
por: Mononen, N, et al.
Publicado: (2001)

Aromatase and 5-alpha reductase gene expression: modulation by pain and morphine treatment in male rats
por: Aloisi, Anna Maria, et al.
Publicado: (2010)

5-Alpha-Reductase 2 Deficiency in a Woman with Primary Amenorrhea
por: Maleki, Nasrollah, et al.
Publicado: (2013)

Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review
por: Escamilla-Cruz, Mariana, et al.
Publicado: (2023)

Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
por: Mumin, Nuramalina H., et al.
Publicado: (2019)

Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro
por: Youn, Dong-Hyun, et al.
Publicado: (2018)

Androgen Regulation of 5α-Reductase Isoenzymes in Prostate Cancer: Implications for Prostate Cancer Prevention
por: Li, Jin, et al.
Publicado: (2011)

Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults
por: Kumar, Abhishek, et al.
Publicado: (2019)

Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?
por: Kosaka, Takeo, et al.
Publicado: (2014)

The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor, 5α-reductase 1 and 5α-reductase 2 in TRAMP mouse prostates
por: Opoku-Acheampong, Alexander B., et al.
Publicado: (2017)

Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity
por: Kosaka, Takeo, et al.
Publicado: (2013)

5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data
por: Del Giudice, Francesco, et al.
Publicado: (2023)

Conducting multiple mini-interviews in the midst of COVID-19 pandemic
por: Kok, Kenneth Yy, et al.
Publicado: (2021)

Phytochemical Analysis of Agrimonia pilosa Ledeb, Its Antioxidant Activity and Aldose Reductase Inhibitory Potential
por: Kim, Set Byeol, et al.
Publicado: (2017)

Clinical presentations and molecular characterization of Indonesian children with 5 alpha-reductase deficiency
por: Marzuki, Nanis S, et al.
Publicado: (2013)

Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
por: Kim, Jae Heon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q6ojh0a5bu241s81rce2ifs20j